OPEN Health and Pharmerit Combine the Best of Both Worlds
We are an integrated, global team of research and communication experts working together to improve the lives of patients worldwide.
Why Pharmerit and OPEN Health?
Together, we offer a truly comprehensive suite of services to identify and address evidence gaps and deliver world class communications across a wide range of media. Combined with our broad scope of therapeutic expertise, we produce results and solutions that are of the highest quality.
What We Do
Our multidisciplinary teams work across 4 Centers of Excellence to communicate a product’s value.
Modeling and Meta-Analysis
Developing tools to inform policy decision makers about the clinical and health economic consequences of health technologies
Real-World Evidence and Data Analytics
Designing studies using data from patient medical records, insurance claims, and clinical trials.
Patient-Centered Outcomes
Developing, refining, and analyzing outcomes, quantifying values, and optimizing study designs to highlight the patient voice.
Strategic Market Access
Communicating evidence regarding unmet needs and the benefits and costs of treatment innovations to ensure market access.
Latest News and Views
Into the QOL-verse: A Reflection on Quality of Life Valuation Origin Stories
Just a few musings before ISOQOL from your friendly neighborhood researcher.
Methods Maze: Pointers for Selecting Survival Extrapolation Models for Cancer Immunotherapy
Watch the recording of the ISPOR webinar
Meet OPEN Health and Pharmerit Experts at the World Pharma Pricing Market Access and Evidence Congress 2020
Join us to discuss HEOR, market access and real-world evidence.
Solving pharma’s biggest challenges
People are at the heart of our business. Without our incredibly talented people, we couldn’t offer our clients the world-class service they have come to expect.
We know how important it is to support, develop, reward and encourage our team. And that’s just part of what makes Pharmerit – an OPEN Health Company a great place to work.
Latest News
Novel Risk Stratification Algorithm for Estimating the Risk of Death in Patients with Relapsed Multiple Myeloma: External Validation in a Retrospective Chart Review
Novel Risk Stratification Algorithm for Estimating the Risk
Into the QOL-verse: A Reflection on Quality of Life Valuation Origin Stories
Just a few musings before ISOQOL from your friendly neighborhood researcher.
Methods Maze: Pointers for Selecting Survival Extrapolation Models for Cancer Immunotherapy
Watch the recording of the ISPOR webinar
